Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms

Gene

Volumn 531, Issue 1, 2013, Pages 23-30

  Chen, Dong ^a   Chen, Zhiyong ^a   Park, Chanyoung ^a   Centrella, Michael ^a   McCarthy, Thomas ^a   Chen, Li ^a   Al Omari, Ahmed ^a   Moeckel, Gilbert W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; AP1; Fibronectin; IgF1 R; JNK; Mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; FIBRONECTIN; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FIBROBLAST; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; KIDNEY CELL; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RAT; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIVATOR PROTEIN 1; ALDOSTERONE; ANGIOTENSIN RECEPTOR BLOCKER; AP1; ARB; C-JUN NH2-TERMINAL PROTEIN KINASE; CHRONIC KIDNEY DISEASE; CKD; DMEM; DULBECCO'S MODIFIED EAGLE'S MEDIUM; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERK1/2; EXTRACELLULAR SIGNAL-REGULATED KINASE; FBS; FETAL BOVINE SERUM; FIBRONECTIN; GLUCOCORTICOID RESPONSIVE ELEMENT; GRE; IGF1-R; INSULIN-LIKE GROWTH FACTOR-1; JNK; MADIN-DARBY CANINE KIDNEY EPITHELIAL CELLS; MCR; MDCK; MINERALOCORTICOID RECEPTOR; MMTV; MOUSE MAMMARY TUMOR VIRUS; PCNA; PKC; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN KINASE C; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC; SRC; TGF-Β; TRANSFORMING GROWTH FACTOR BETA; VASCULAR SMOOTH MUSCLE CELL; VSMC;

ALDOSTERONE; ANIMALS; CELL LINE; CELL NUCLEUS; FIBROBLASTS; FIBRONECTINS; KIDNEY; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RECEPTOR, IGF TYPE 1; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 84884814686     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.08.047     Document Type: Article

References (40)

1. Arriza J.L., et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
2. Beesley A.H., Hornby D., White S.J. Regulation of distal nephron K+ channels (ROMK) mRNA expression by aldosterone in rat kidney. J. Physiol. 1998, 509(Pt 3):629-634.
3. Bianchi S., Bigazzi R., Campese V.M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am. J. Kidney Dis. 2005, 46:45-51.
4. Bohle A., Strutz F., Muller G.A. On the pathogenesis of chronic renal failure in primary glomerulopathies: a view from the interstitium. Exp. Nephrol. 1994, 2:205-210.
5. Brem, et al. Direct Fibrogenic Effects of Aldosterone on Normotensive Kidney: An Effect Modified by 11{beta}-HSD Activity. Am. J. Physiol. Renal. Physiol. 2010, 298(5):F1178-F1187. (May).
6. Brown N.J., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000, 58:1219-1227.
7. Bunda S., et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 2009, 284:16633-16647.
8. Callera G.E., et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005, 46:1032-1038.
9. Christ M., Eisen C., Aktas J., Theisen K., Wehling M. The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes. J. Clin. Endocrinol. Metab. 1993, 77:1452-1457.
10. Del Vecchio L., Procaccio M., Vigano S., Cusi D. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat. Clin. Pract. Nephrol. 2007, 3:42-49.
11. Epstein M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 2006, 1:940-951.
12. Feria I., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003, 63:43-52.
13. Fujisawa G., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004, 66:1493-1502.
14. Gekle M., Freudinger R., Mildenberger S., Schenk K., Marschitz I., Schramek H. Rapid activation of Na+/H+-exchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2. Pflugers Arch. 2001, 441:781-786.
15. Gekle M., Freudinger R., Mildenberger S., Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am. J. Physiol. Renal Physiol. 2002, 282:F669-F679.
16. Greene E.L., Kren S., Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 1996, 98:1063-1068.
17. Grossmann C., Freudinger R., Mildenberger S., Krug A.W., Gekle M. Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am. J. Physiol. Renal Physiol. 2004, 286:F1226-F1231.
18. Grossmann C., Krug A.W., Freudinger R., Mildenberger S., Voelker K., Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E1790-E1800.
19. Han K.H., et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 2006, 70:111-120.
20. Holzman J.L., Liu L., Duke B.J., Kemendy A.E., Eaton D.C. Transactivation of the IGF-1R by aldosterone. Am. J. Physiol. Renal Physiol. 2007, 292:F1219-F1228.
21. Huang L.L., Nikolic-Paterson D.J., Ma F.Y., Tesch G.H. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signalling. Nephron Exp. Nephrol. 2012, 120:e115-e122.
22. Johnson D.W., Saunders H.J., Baxter R.C., Field M.J., Pollock C.A. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 1998, 54:747-757.
23. Lai L., Chen J., Hao C.M., Lin S., Gu Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem. Biophys. Res. Commun. 2006, 348:70-75.
24. Lakkis J., Lu W.X., Weir M.R. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr. Hypertens. Rep. 2003, 5:408-417.
25. Lemarie C.A., et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ. Res. 2009, 105:852-859.
26. McCarthy T.L., Ji C., Chen Y., Kim K., Centrella M. Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3',5'-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts. Endocrinology 2000, 141:127-137.
27. McCarthy T.L., Chang W.Z., Liu Y., Centrella M. Runx2 integrates estrogen activity in osteoblasts. J. Biol. Chem. 2003, 278:43121-43129.
28. Medema R.H., Klompmaker R., Smits V.A., Rijksen G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998, 16:431-441.
29. Nagai Y., et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005, 46:1039-1045.
30. Nishiyama A., et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004, 43:841-848.
31. Oberleithner H., Weigt M., Westphale H.J., Wang W. Aldosterone activates Na+/H+ exchange and raises cytoplasmic pH in target cells of the amphibian kidney. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:1464-1468.
32. Pippal J.B., Fuller P.J. Structure-function relationships in the mineralocorticoid receptor. J. Mol. Endocrinol. 2008, 41:405-413.
33. Remuzzi G., Cattaneo D., Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J. Am. Soc. Nephrol. 2008, 19:1459-1462.
34. Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
35. Schjoedt K.J., Andersen S., Rossing P., Tarnow L., Parving H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936-1939.
36. Schjoedt K.J., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005, 68:2829-2836.
37. Tseng L., Tang M., Wang Z., Mazella J. Progesterone receptor (hPR) upregulates the fibronectin promoter activity in human decidual fibroblasts. DNA Cell Biol. 2003, 22:633-640.
38. Weigert C., et al. Evidence for a novel TGF-beta1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 2003, 52:527-535.
39. Xue C., Siragy H.M. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005, 46:584-590.
40. Zhang, et al. Aldosterone promotes fibronectin synthesis in rat mesangial cells via ERK1/2-stimulated Na-H+ exchanger isoform 1. Am. J. Nephrol. 2010, 31(1):75-82.